Bogdan -Stefan Negreanu-Pirjol | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Bogdan -Stefan Negreanu-Pirjol | Pharmaceutical Science | Best Researcher Award

Head of Analytical and Instrumental Chemistry at Ovidius University of Constanta, Romania

Assoc. Prof. Dr. Bogdan-Ștefan Negreanu-Pîrjol is a distinguished academic and researcher, celebrated for his innovative contributions to the fields of analytical chemistry and pharmacy. With a prolific career spanning over two decades, Dr. Negreanu-Pîrjol has made significant advancements in biocomposites, pharmaceutical formulations, and instrumental analysis. His dedication to education, research, and mentorship has solidified his reputation as a leader in his field. He has published extensively, obtained numerous patents, and played a pivotal role in shaping the next generation of professionals and researchers through his teaching and collaborative initiatives.

Professional Profile

Education

Dr. Negreanu-Pîrjol earned his Ph.D. in Chemistry from the University of Bucharest, with groundbreaking research on biocomposite fertilizers that showcased his ability to merge scientific innovation with practical application. He also holds a Habilitation Certificate in Pharmacy from Ovidius University of Constanța, enabling him to mentor doctoral students and lead advanced research projects. His academic journey began with a Bachelor’s degree in Chemistry, where he excelled in both theoretical and practical aspects of the discipline. Over the years, he has further enhanced his expertise through certifications in environmental auditing, project management, and laboratory quality control, reflecting his commitment to lifelong learning.

Professional Experience

Dr. Negreanu-Pîrjol has held multiple influential positions at Ovidius University of Constanța, where he currently serves as an Associate Professor in the Faculty of Pharmacy. His teaching portfolio includes courses in analytical chemistry, instrumental analysis, and quality control, tailored to meet the needs of pharmacy students. Beyond academia, he has contributed to numerous industry projects, serving as a consultant and scientific officer in areas such as environmental monitoring and pharmaceutical product development. His leadership in funded research projects and his role as a reviewer for high-impact journals highlight his standing as a respected expert in his field.

Research Interests

Dr. Negreanu-Pîrjol’s research interests encompass a wide range of topics within chemistry and pharmacy. He is particularly focused on the development of biocomposite materials, innovative pharmaceutical formulations, and advanced analytical techniques. His interdisciplinary approach often bridges chemistry with environmental science and healthcare, aiming to create sustainable solutions and improve patient outcomes. He is also deeply interested in exploring the applications of nanotechnology and artificial intelligence in pharmaceutical sciences, which align with emerging trends and global research priorities.

Research Skills

Dr. Negreanu-Pîrjol possesses exceptional skills in analytical and instrumental chemistry, with expertise in techniques such as chromatography, spectroscopy, and electrochemical analysis. He is also proficient in designing and executing complex experiments, data interpretation, and statistical analysis. His innovative mindset is evident in his 16 patents and numerous peer-reviewed publications, which demonstrate his ability to translate theoretical concepts into practical applications. Additionally, his experience in project management and grant writing has enabled him to lead multidisciplinary teams and secure funding for impactful research projects.

Awards and Honors

Dr. Negreanu-Pîrjol’s contributions to science and education have been recognized through various awards and honors. He has received accolades for his research excellence, including national and international distinctions for his work on biocomposite materials and pharmaceutical innovations. His role as a mentor has also been acknowledged through teaching awards, reflecting his commitment to nurturing talent and fostering academic excellence. Furthermore, his patents and publications have earned him a reputation as a trailblazer in his field, cementing his legacy as a thought leader.

Conclusion

Assoc. Prof. Dr. Bogdan-Ștefan Negreanu-Pîrjol exemplifies the qualities of an outstanding researcher, educator, and innovator. His extensive academic background, prolific research output, and unwavering dedication to advancing science make him a worthy candidate for prestigious recognitions like the Best Researcher Award. By integrating cutting-edge technologies with practical applications, he continues to contribute to the betterment of society while inspiring future generations of scientists and professionals.

Publication Top Notes

  1. Title: Aquatic plants used for heavy metals phytoaccumulation and phytoremediation potential: A review
    Authors: Negreanu-Pirjol, B.-S., Popovidu, D.R., Negreanu-Pirjol, T.
    Year: 2024
  2. Title: The Chemical Profile, Antioxidant, and Anti-Lipid Droplet Activity of Fluid Extracts from Romanian Cultivars of Haskap Berries, Bitter Cherries, and Red Grape Pomace for the Management of Liver Steatosis
    Authors: Craciunescu, O., Seciu-Grama, A.-M., Mihai, E., Ranca, A., Negreanu-Pirjol, B.-S.
    Year: 2023
  3. Title: Natural Bio-Compounds from Ganoderma lucidum and Their Beneficial Biological Actions for Anticancer Application: A Review
    Authors: Cadar, E., Negreanu-Pirjol, T., Pascale, C., Tomescu, C.L., Ionescu, A.-M.
    Year: 2023
  4. Title: Biocompounds from Green Algae of Romanian Black Sea Coast as Potential Nutraceuticals
    Authors: Cadar, E., Negreanu-Pirjol, T., Sirbu, R., Axente, E.R., Ionescu, A.-M.
    Year: 2023
  5. Title: Health Benefits of Antioxidant Bioactive Compounds in the Fruits and Leaves of Lonicera caerulea L. and Aronia melanocarpa (Michx.) Elliot
    Authors: Negreanu-Pirjol, B.-S., Oprea, O.C., Negreanu-Pirjol, T., Cosma, M., Popoviciu, D.R.
    Year: 2023
  6. Title: In Vitro Hypoglycemic Potential, Antioxidant and Prebiotic Activity after Simulated Digestion of Combined Blueberry Pomace and Chia Seed Extracts
    Authors: Mihai, E., Negreanu-Pirjol, B.-S., Craciunescu, O., Ghenea, A.-M., Negreanu-Pirjol, T.
    Year: 2023
  7. Title: Jellyfishes—Significant Marine Resources with Potential in the Wound-Healing Process: A Review
    Authors: Cadar, E., Pesterau, A.-M., Sirbu, R., Negreanu-Pirjol, B.S., Tomescu, C.L.
    Year: 2023
  8. Title: Xanthophyll pigments dietary supplements administration and retinal health in the context of increasing life expectancy trend
    Authors: Jurja, S., Negreanu-Pirjol, T., Vasile, M., Coviltir, V., Negreanu-Pirjol, B.-S.
    Year: 2023
  9. Title: Preliminary Data Regarding Bioactive Compounds and Total Antioxidant Capacity of Some Fluid Extracts of Lonicera caerulea L. Berries
    Authors: Negreanu-Pirjol, B.-S., Negreanu-Pirjol, T., Popoviciu, D.R., Motelica, L., Vasile, M.
    Year: 2023
  10. Title: Marine Bioactive Compounds Derived from Macroalgae as New Potential Players in Drug Delivery Systems: A Review
    Authors: Negreanu-Pirjol, B.-S., Negreanu-Pirjol, T., Popoviciu, D.R., Anton, R.-E., Prelipcean, A.-M.
    Year: 2022

 

 

Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Xian Zheng | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Xian Zheng | Pharmaceutical Science | Best Researcher Award

Assistant research Fellow of Affiliated Kunshan Hospital of Jiangsu University, China.

Xian Zheng is a prominent researcher specializing in Chinese herbal drugs, natural products, and nonalcoholic fatty liver disease (NAFLD). With a Ph.D. in Chinese pharmacy from China Pharmaceutical University, he currently serves as an Assistant Researcher at the Affiliated Kunshan Hospital of Jiangsu University and a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics. Zheng leads several high-impact projects, including studies on arjunolic acid and liposome-based therapies for NAFLD, supported by major funding bodies like the National Natural Science Foundation of China. His research is well-regarded, with numerous publications in leading journals such as Phytomedicine and J Functional Foods. Zheng has been honored with awards like Jiangsu Double Innovation Doctor and Gusu Health Talents Plan-“Class D special talents”. His work showcases significant contributions to the field, marked by a strong publication record and leadership in innovative research.

Profile
Education

Xian Zheng’s educational background reflects a strong foundation in pharmacology and pharmacy. He earned his Ph.D. in Chinese Pharmacy from the College of Traditional Chinese Medicine at China Pharmaceutical University, Nanjing, in December 2021, under the supervision of Professor Zhiqi Yin. Prior to this, he completed his Master of Science in Pharmacology at the School of Pharmacy, Xuzhou Medical University, in June 2018, guided by Professor Yi Liu. Zheng’s academic journey began with a Ph.D. in Pharmacy from the School of Pharmacy, Nanjing2 University of Chinese Medicine, which he completed in June 2015. This extensive education, encompassing both traditional Chinese medicine and modern pharmacology, has provided him with a robust understanding of drug development and therapeutic applications, particularly in the realm of natural products and their effects on nonalcoholic fatty liver disease.

Professional Experience

Xian Zheng currently serves as an Assistant Researcher at the Department of Pharmacy, Affiliated Kunshan Hospital of Jiangsu University, where he has been contributing to cutting-edge research since February 2022. Additionally, he is a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics, a position he has held since October 2022. Zheng’s professional journey includes significant achievements in studying Chinese herbal drugs and natural products, particularly in the context of nonalcoholic fatty liver disease (NAFLD). He leads multiple high-profile research projects funded by prestigious organizations such as the National Natural Science Foundation of China and the Gusu Health Talent Research Project. His expertise in pharmacology and his leadership in these research initiatives highlight his dedication and impact in advancing therapeutic strategies for NAFLD and related conditions.

Research Interest

Xian Zheng’s research interests primarily focus on Chinese herbal drugs and natural products, with a particular emphasis on their therapeutic potential for nonalcoholic fatty liver disease (NAFLD). His work explores innovative treatment approaches, such as the dual NAMPT activation theory, and the development of liposome-based drug delivery systems to enhance the efficacy of herbal compounds. Zheng’s research aims to uncover the underlying mechanisms of these treatments, such as their effects on metabolic pathways and cellular functions. He is dedicated to advancing the understanding of how traditional herbal remedies can be optimized and integrated into modern therapeutic strategies for complex liver diseases. By combining traditional pharmacological insights with contemporary biomedical techniques, Zheng seeks to bridge the gap between ancient remedies and modern medicine, ultimately improving clinical outcomes for patients with NAFLD and contributing to the broader field of natural product research.

Research Skills

Xian Zheng demonstrates exceptional research skills, particularly in the domain of pharmacology and natural product research. His expertise encompasses a comprehensive understanding of Chinese herbal drugs and their therapeutic applications, with a specific focus on nonalcoholic fatty liver disease (NAFLD). Zheng excels in designing and leading innovative research projects, such as exploring dual NAMPT activation and developing liposome-based therapies for NAFLD. His ability to secure funding from prestigious organizations, including the National Natural Science Foundation of China, underscores his proficiency in research proposal development and project management. Zheng’s analytical skills are evident in his extensive publication record in reputable journals, where he contributes to advancing knowledge in his field. His role as a part-time postdoctoral researcher further reflects his commitment to scientific inquiry and collaboration. Overall, Zheng’s research skills are marked by a blend of innovative thinking, effective project leadership, and a strong publication track record.

Awards and Recognition

Xian Zheng has earned notable recognition in his field through a series of prestigious awards and honors. His achievements include being named a Jiangsu Double Innovation Doctor, which acknowledges his exceptional contributions to innovative research in Chinese pharmacy. Additionally, Zheng is distinguished as a “Class D special talents” under the Gusu Health Talents Plan, underscoring his impactful work in the realm of natural products and nonalcoholic fatty liver disease. He was also recognized as a Kunshan Youth Post Expert in 2022 and a Suzhou Youth Post Expert in 2023, highlighting his significant contributions to the scientific community and his leadership in advancing research. These accolades reflect Zheng’s dedication and impact in the field of pharmacology and his commitment to advancing therapeutic approaches through his innovative research efforts.

Conclusion

Dr. Tao Song is a strong candidate for the Best Researcher Award due to his significant contributions to the field of catalysis and green chemistry. His innovative research and high-impact publications demonstrate a clear potential for future leadership in the field. To further strengthen his candidacy, Dr. Song could focus on expanding the impact of his research through interdisciplinary collaborations and leadership roles. Given his achievements and potential, Dr. Song is well-suited for recognition as a leading researcher in his field.

Publications Top Notes

  1. Arjunolic Acid from Cyclocarya paliurus Selectively Inhibits Glucagon Secretion from α Cells and Ameliorates Diabetes via Ephrin-A1 and EphA4 Interaction
    • Authors: Fang, C.-Q., Teng, Y., Wang, Y.-T., Cao, X.-L., Jiang, C.-H.
    • Year: 2022
  2. Aloin A Prevents Ulcerative Colitis in Mice by Enhancing the Intestinal Barrier Function via Suppressing the Notch Signaling Pathway
    • Authors: Jiang, H., Shi, G.-F., Fang, Y.-X., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 11
  3. Protective Effects of Cyclocarya paliurus on Hyperuricemia and Urate-Induced Inflammation
    • Authors: Zhu, L.-H., Xu, Y.-Y., Zhu, L.-P., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 9
  4. Cyclocarya paliurus Triterpenoids Attenuate Glomerular Endothelial Injury in Diabetic Rats via ROCK Pathway
    • Authors: Yang, R., Xu, S., Zhang, X., Yin, Z., Pan, K.
    • Year: 2022
    • Citations: 8
  5. Chrysin Inhibits Hepatocellular Carcinoma Progression Through Suppressing Programmed Death Ligand 1 Expression
    • Authors: Rong, W., Wan, N., Zheng, X., Gao, Z.-J., Zhang, J.
    • Year: 2022
    • Citations: 17
  6. New Dammarane-Type Triterpenoid Saponins from Gynostemma pentaphyllum and Their Sirt1 Agonist Activity
    • Authors: Lou, Y.-Y., Zheng, X., Huang, Y.-P., Yin, Z.-Q., Pan, K.
    • Year: 2021
    • Citations: 12
  7. Arjunolic Acid from Cyclocarya paliurus Ameliorates Nonalcoholic Fatty Liver Disease in Mice via Activating Sirt1/AMPK, Triggering Autophagy and Improving Gut Barrier Function
    • Authors: Zheng, X., Zhang, X.-G., Liu, Y., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 6
  8. Aloe Vera Mitigates Dextran Sulfate Sodium-Induced Rat Ulcerative Colitis by Potentiating Colon Mucus Barrier
    • Authors: Shi, G., Jiang, H., Feng, J., Jiang, C., Zhang, J.
    • Year: 2021
    • Citations: 30
  9. Four New Dammarane Triterpenoid Glycosides from the Leaves of Cyclocarya paliurus and Their SIRT1 Activation Activities
    • Authors: Zhu, L.-P., Yang, H.-M., Zheng, X., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 7
  10. Gypenoside LVI Improves Hepatic LDL Uptake by Decreasing PCSK9 and Upregulating LDLR Expression
    • Authors: Wang, J., Wang, Y.-S., Huang, Y.-P., Yin, Z.-Q., Zhang, J.
    • Year: 2021
    • Citations: 21

 

Justine Benevent | Pharmaceutical Science | Best Scholar Award

Posted on by ScienceFather

Dr. Justine Benevent | Pharmaceutical Science | Best Scholar Award

MCU-PH at CHU Toulouse, INSERM CERPOP, France

Based on the provided information, Justine Benevent appears to be a strong candidate for the Best Scholar Award. Here is a detailed assessment of her suitability, structured by various criteria:

Education

Justine Benevent’s educational background is distinguished by a series of advanced degrees in pharmacology and related fields. She holds a Diplôme d’état de Docteur en Pharmacie from Bordeaux, providing a comprehensive foundation in pharmacy. She further specialized with a DESC de Pharmacologie médicale from Bordeaux, focusing on medical pharmacology. Her academic journey continued with a Thèse d’Université de Pharmacologie in Toulouse, where she engaged in in-depth research. She also earned a Diplôme Universitaire de pédagogie en Santé from Toulouse, enhancing her skills in health education. Additionally, she completed the DES Pharmacie hospitalière from Bordeaux, highlighting her expertise in hospital pharmacy. These qualifications reflect her extensive training and dedication to the field of pharmacology, underpinning her expertise and contributions to research and clinical practice.

Research Contributions

Justine Benevent has made significant research contributions in pharmacology, with a focus on medications, reproduction, pregnancy, and breastfeeding. She has a solid publication record with 33 papers, including 6 as the first author, and a notable h-index of 10, indicating her research impact and recognition in the academic community.

Geographic Impact

Her research has a wide geographic impact, involving collaborations with international institutions such as PharmaSafe at the University of Oslo, Norway. Her work with the European Consortium IMI ConcePTION highlights her ability to engage in research that transcends national boundaries, addressing health issues relevant to diverse populations.

Collaborative Efforts

Justine Benevent is actively involved in several collaborative research projects and networks. She is a partner of the European Consortium IMI ConcePTION, a member of the national network REGARDs, and participates in various working groups, including those focused on mental health and reproductive risks of drugs. These collaborations demonstrate her commitment to multi-disciplinary and international research efforts.

Applied Research

Her research is highly applied, focusing on real-world health issues such as the effects of medications during pregnancy and breastfeeding. Her role in the project “Maison des Femmes” at CHU de Toulouse, aimed at improving healthcare for women, underscores her dedication to applying research findings to enhance community health and well-being.

Specific Projects and Publications

Justine Benevent has led and contributed to numerous impactful projects. Her work within the “Santé périnatale, pédiatrique et des adolescents” team at CERPOP addresses critical aspects of perinatal and pediatric health. She has also been involved in leading two projects within the IMI ConcePTION consortium, further highlighting her leadership in significant research initiatives.

Environmental Health

While her primary focus is on pharmacology and reproductive health, her work indirectly impacts environmental health by addressing the safe use of medications during critical periods such as pregnancy and breastfeeding. This contributes to overall community health by ensuring safer pharmaceutical practices.

Vector Control

There is no direct mention of research in vector control in her profile. However, her extensive work in pharmacology and drug safety may intersect with public health strategies that could include elements of vector control indirectly.

Waste Management and Water Quality

Justine Benevent’s profile does not indicate direct involvement in waste management and water quality research. Her expertise lies primarily in pharmacology and clinical research methodology.

Parasitology and Infectious Diseases

Although parasitology and infectious diseases are not explicitly mentioned, her pharmacological research, especially in the context of reproductive health, could contribute to understanding and managing infections that affect pregnant women and infants.

Awards and Recognition

Justine Benevent’s academic and research achievements have been recognized through various positions and memberships, such as her role as Treasurer of the CNPM (Collège National de Pharmacologie Médicale) and her involvement in the French Society of Pharmacology and Therapeutics (SFPT). Her significant publication record and citation count further attest to her recognition in the field.

Conclusion

Justine Benevent is a highly accomplished scholar with a strong background in pharmacology, evidenced by her extensive research contributions, collaborative efforts, and applied research impact. Her work addresses crucial health issues related to medications and reproductive health, making her a deserving candidate for the Best Scholar Award. Her leadership in various national and international research projects and her dedication to improving community health through applied research are particularly commendable.

Publications Top Notes

  1. Teaching pharmacovigilance to French medical students during the COVID-19 pandemic: Interest of distance learning clinical reasoning sessions
    • Authors: F. Montastruc, F. Muscari, I. Tack, G. Durrieu, A. Sommet
    • Year: 2024
  2. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: A systematic review and meta-analysis
    • Authors: L. Saint-Lary, J. Benevent, C. Damase-Michel, V. Leroy, A. Sommet
    • Year: 2023
    • Citations: 2
  3. Drug monitoring in pregnant women: about the Regards network | Surveillance des médicaments chez les femmes enceintes : à propos du réseau Regards
    • Authors: I. Lacroix, M. Araujo, A. Caillet, L. Delteil, C. Damase-Michel
    • Year: 2023
    • Citations: 1
  4. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database
    • Authors: J. Benevent, M. Araujo, S. Karki, S. Tebeka, C. Damase-Michel
    • Year: 2023
    • Citations: 2
  5. Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age?
    • Authors: M. Balon, S. Tessier, C. Damase-Michel, J. Benevent, I. Lacroix
    • Year: 2023
    • Citations: 5
  6. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database
    • Authors: J. Benevent, M. Araujo, A.-B. Beau, I. Lacroix, C. Damase-Michel
    • Year: 2023
    • Citations: 3
  7. Interactions between antiseizure medications and contraception: A study about the knowledge of patients and their specialist physicians
    • Authors: A. Gosset, M. Denuelle, L. Valton, B.énévent, F. Tremollières
    • Year: 2022
    • Citations: 5
  8. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study
    • Authors: J. Benevent, C. Hurault-Delarue, M. Araujo, I. Lacroix, C. Damase-Michel
    • Year: 2022
  9. What changes in prescription patterns of antiemetic medications in pregnant women in France?
    • Authors: C. Hurault-Delarue, M. Araujo, C. Vabre, C. Damase-Michel, I. Lacroix
    • Year: 2021
    • Citations: 4
  10. Maternal Medication Use and Childhood Cancer in Offspring-Systematic Review and Considerations for Researchers
    • Authors: S. Hjorth, C.H. Hemmingsen, J. Benevent, M. Hargreave, H. Nordeng
    • Year: 2021
    • Citations: 2